Capricor Therapeutics (NASDAQ:CAPR - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. They currently have a $40.00 target price on the biotechnology company's stock.
A number of other research analysts have also recently weighed in on the company. StockNews.com upgraded Capricor Therapeutics from a "sell" rating to a "hold" rating in a report on Wednesday, January 24th. Cantor Fitzgerald started coverage on Capricor Therapeutics in a research note on Friday, January 5th. They set an "overweight" rating and a $8.00 price objective on the stock.
Get Our Latest Research Report on CAPR
Capricor Therapeutics Stock Up 2.2 %
Shares of CAPR stock traded up $0.11 during mid-day trading on Thursday, hitting $5.15. 387,928 shares of the company's stock were exchanged, compared to its average volume of 299,000. Capricor Therapeutics has a fifty-two week low of $2.68 and a fifty-two week high of $8.22. The stock has a market cap of $162.23 million, a price-to-earnings ratio of -5.75 and a beta of 3.99. The stock has a 50-day simple moving average of $5.58 and a two-hundred day simple moving average of $4.34.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its earnings results on Thursday, February 29th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.21. Capricor Therapeutics had a negative return on equity of 299.67% and a negative net margin of 88.52%. The firm had revenue of $12.09 million for the quarter, compared to analysts' expectations of $5.80 million. As a group, analysts anticipate that Capricor Therapeutics will post -0.83 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Capricor Therapeutics stock. Jump Financial LLC bought a new position in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 52,800 shares of the biotechnology company's stock, valued at approximately $258,000. Jump Financial LLC owned about 0.17% of Capricor Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 21.68% of the stock is currently owned by institutional investors.
Capricor Therapeutics Company Profile
(
Get Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Further Reading
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
